.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD25_MetforminSaxagliptinAndDapaglifl.MetforminSaxagliptinAndDapaglifl .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD25_MetforminSaxagliptinAndDapaglifl.MetforminSaxagliptinAndDapaglifl| name: | MetforminSaxagliptinAndDapagliflozin |
| ATC code: | A10BD25 |
| route: | oral |
| n-compartments | 1 |
Metformin, saxagliptin, and dapagliflozin is a fixed-dose combination oral medication used for the management of type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent, saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, and dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Together, these drugs help improve glycemic control in adults with type 2 diabetes. This combination is approved for clinical use in various countries.
Pharmacokinetic parameters estimated for healthy adult subjects based on published data for the individual components, as studies on the exact combination are not available.